Prof. Jinhua Wang 王金华
Chief Physician, Professor
Department of Gynecologic Oncology Surgery, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of gynecologic tumors, with a focus on surgical management. Expertise includes retroperitoneal lymph node dissection for ovarian cancer, vascularized autologous ovarian transplantation, and modified radical incision for cervical cancer.
Dr. Wang holds a PhD in Surgery from Nanjing University and serves as Director of Medical Affairs at Jiangsu Cancer Hospital. Trained in general surgery and gynecologic oncology, Dr. Wang conducted research at the Arizona Cancer Center. The doctor established ovarian cancer cell lines to study drug resistance and has published over 30 papers.
Professional roles
- Member, Gynecologic Oncology Professional Committee, Jiangsu Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Surgical Oncology
- Editorial Board Member, Oncology
- Reviewer, Chemotherapy
Name order: in Chinese the family name comes first (Wang Jinhua). Papers usually list the name as Jinhua Wang or Wang J.
Selected publications
25 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biomed Pharmacother, 2025 (senior author): AS-IV inhibits the progression of ovarian cancer by targeting the circ_0124787/miR-6875-3p/IL-1β axis. PubMed 41166894
- Am J Reprod Immunol, 2025 (senior author): SMURF2 Inhibits Autophagy and Growth in Ovarian Cancer by Regulating the RACK1/AKT/mTOR Pathway. PubMed 40824172
- Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2024 (senior author): [Tumor-associated macrophages promote pre-metastatic niche formation in ovarian cancer]. PubMed 39750054
- Am J Cancer Res, 2023 (senior author): IGF2BP3-mediated regulation of GLS and GLUD1 gene expression promotes treg-induced immune escape in human cervical cancer. PubMed 38058838
- Front Surg, 2022 (senior author): No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study. PubMed 36171817
- Appl Biochem Biotechnol, 2022 (senior author): LncRNA LINC00665 Promotes Ovarian Cancer Cell Proliferation and Inhibits Apoptosis via Targeting miR-181a-5p/FHDC. PubMed 35524876
- Front Genet, 2022 (senior author): CircATRNL1 and circZNF608 Inhibit Ovarian Cancer by Sequestering miR-152-5p and Encoding Protein. PubMed 35281849
- Onco Targets Ther, 2020 (senior author): The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report. PubMed 32547077
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion